New therapeutic strategies in acute lymphocytic leukemia
LM Man, AL Morris, M Keng - Current hematologic malignancy reports, 2017 - Springer
Most drugs used in standard regimens for acute lymphoblastic leukemia (ALL) were
developed more than 30 years ago. Since that time, several new drugs have been …
developed more than 30 years ago. Since that time, several new drugs have been …
A review of new agents evaluated against pediatric acute lymphoblastic leukemia by the Pediatric Preclinical Testing Program
L Jones, H Carol, K Evans, J Richmond, PJ Houghton… - Leukemia, 2016 - nature.com
Acute lymphoblastic leukemia (ALL) in children exemplifies how multi-agent chemotherapy
has improved the outcome for patients. Refinements in treatment protocols and …
has improved the outcome for patients. Refinements in treatment protocols and …
The influence of exendin-4 intervention on non-obese diabetic mouse blood and the pancreatic tissue immune microenvironment
J He, C Lian, Y Fang, J Wu… - Experimental and …, 2016 - spandidos-publications.com
The aim of the study was to determine the influence of exendin-4 intervention on non‑obese
diabetic (NOD) mouse blood and the pancreatic tissue immune microenvironment. A total of …
diabetic (NOD) mouse blood and the pancreatic tissue immune microenvironment. A total of …
Dosing regimens for use in treating myelofibrosis and MPN-related disorders with navitoclax
J Hayslip, LM Holes, S Mensing… - US Patent 11,285,159, 2022 - Google Patents
US11285159B2 - Dosing regimens for use in treating myelofibrosis and MPN-related disorders
with navitoclax - Google Patents US11285159B2 - Dosing regimens for use in treating …
with navitoclax - Google Patents US11285159B2 - Dosing regimens for use in treating …